Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Notebook: Pricing Mistrust Needs Open Debate; Rasi Nears EMA Return; Market Turmoil Affects IPOs

Executive Summary

The EU’s Health Commissioner called for an open debate on pharmaceutical pricing with industry, while Guido Rasi prepares for part two of helming the European Medicines Agency and German big pharmas Bayer and Merck KGaA completed business restructuring. More developments in this month's column.


Related Content

Acacia's Euronext Listing To Help Target Unmet US PONV Market
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure
European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger
Italian Move Plugs Big Gap In Future EU Patent System
French Industry Rages Over €1.7bn Drug Savings Plan
European Notebook: Drug Pricing Collaborations; Biosimilar Switching; Scientific Advice
EMA Leadership Goes To Pott After Rasi Retroactively Unhired


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts